Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dianthus Therapeutics issues 52,000 stock options as employment inducement awards to four new non-executive hires under a Nasdaq-compliant plan.

Rhea-AI Summary

Dianthus Therapeutics (DNTH) granted equity inducement awards on September 1, 2026 to four newly hired, non-executive employees under Nasdaq Listing Rule 5635(c)(4). The awards were approved by the independent Compensation Committee as material inducements for employment.

The inducement grants consist of non-qualified stock options to purchase an aggregate of 52,000 shares of common stock, with a 10-year term and an exercise price of $106.62 per share. The options vest 25% on the first anniversary of the vesting commencement date and then in equal monthly installments over the following 36 months. The grants are subject to the company’s Equity Inducement Plan and individual stock option agreements.

Market Context

The August 3 inducement-grant announcement was followed by a 4.13% DNTH move, providing a directly c...

Analysis

The August 3 inducement-grant announcement was followed by a 4.13% DNTH move, providing a directly comparable historical reference. The current award size and active S-3 add dilution-related context; subsequent hiring execution remains important.

Key Figures

Grant date: September 1, 2026 New employees: 4 employees Options granted: 52,000 shares +4 more

7 metrics

Grant date September 1, 2026 Inducement awards

New employees 4 employees Newly hired, non-executive employees

Options granted 52,000 shares Aggregate non-qualified stock options

Exercise price $106.62 per share Stock options

Option term 10 years Non-qualified stock options

Initial vesting 25% Vests on the first anniversary of the vesting commencement date

Remaining vesting period 36 months Equal monthly installments after the first anniversary

Historical Context

5 past events · Latest: Sep 01 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Sep 01	Investor conferences	Neutral	+1.0%	Participation announced for three September investor conferences and related executive meetings
Aug 10	Board appointments	Neutral	-3.0%	Agomab proposed appointments of Dianthus and CRISPR executives to its board
Aug 04	Q2 earnings report	Neutral	+1.9%	Quarterly results combined operating progress with higher expenses and a larger net loss
Aug 04	DNTH312 announcement	Positive	+4.1%	New bifunctional fusion protein showed comparable potency and extended half-life characteristics
Aug 03	Inducement stock grants	Neutral	+4.1%	Equity awards covered six newly hired employees and 87,000 common shares

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent DNTH news was followed by positive price reactions in four of five listed events, although most announcements were neutral or mixed in sentiment.

Key Terms

nasdaq listing rule 5635(c)(4), non-qualified stock options

2 terms

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

non-qualified stock options financial

"consist of non-qualified stock options to purchase an aggregate"

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK and WALTHAM, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it granted equity awards on September 1, 2026, to four newly-hired, non-executive employees. The inducement grants were approved by the Company's independent Compensation Committee and were made as material inducements to acceptance of employment with Dianthus in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement grants consist of non-qualified stock options to purchase an aggregate of 52,000 shares of the Company's common stock with a 10-year term and an exercise price of $106.62 per share. The options vest as to 25% on the first anniversary of the vesting commencement date and in equal monthly installments for the following 36 months. The inducement grants are subject to the terms and conditions of the Dianthus Therapeutics, Inc. Equity Inducement Plan, and the terms and conditions of a stock option agreement.

About Dianthus Therapeutics
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who aim to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.

To learn more, please visit www.dianthustx.com and follow us on LinkedIn. 

Contact
Jennifer Davis Ruff
Dianthus Therapeutics
jdavisruff@dianthustx.com

FAQ

What equity inducement grants did Dianthus Therapeutics (DNTH) announce on September 2, 2026?

Dianthus Therapeutics announced non-qualified stock option inducement grants to four newly hired, non-executive employees, covering an aggregate of 52,000 shares of common stock. These options were granted on September 1, 2026 and approved by the company’s independent Compensation Committee.

What are the key terms of the Dianthus Therapeutics (DNTH) inducement stock options?

The inducement stock options have a 10-year term and an exercise price of $106.62 per share. Vesting occurs 25% on the first anniversary of the vesting commencement date, with the remaining 75% vesting in equal monthly installments over the next 36 months.

How do the Dianthus Therapeutics (DNTH) inducement grants comply with Nasdaq Listing Rule 5635(c)(4)?

The stock option awards were approved by the company’s independent Compensation Committee and were granted as material inducements to employment for four new non-executive employees, which the company states is in accordance with Nasdaq Listing Rule 5635(c)(4).

How many employees received inducement stock options from Dianthus Therapeutics (DNTH)?

Four newly hired, non-executive employees received the inducement stock option grants from Dianthus Therapeutics. In total, these options give the right to purchase 52,000 shares of the company’s common stock, subject to the stated vesting schedule and plan terms.

Under what plan are the Dianthus Therapeutics (DNTH) inducement stock options granted?

The inducement stock options are granted under the Dianthus Therapeutics Equity Inducement Plan and are subject to its terms and conditions, as well as the provisions of an individual stock option agreement for each recipient.